Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06375512
Status:
RECRUITING
Last Update Posted:
2024-06-26
First Post:
2024-04-17
Brief Title:
A Study to Describe the Safety Reactogenicity and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine IN001 in Healthy Participants
Sponsor:
Shenzhen Shenxin Biotechnology Co Ltd
Organization:
Shenzhen Shenxin Biotechnology Co Ltd
Study Overview
Official Title:
A Phase 1 Randomized Multicenter Double-blind Dose-ranging Study to Evaluate the Safety Reactogenicity and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine IN001 in Healthy Participants 50 to 69 Years Old
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will evaluate the safety tolerability and immunogenicity your immune systems reaction of the study vaccine called Herpes Zoster IN001 mRNA Vaccine IN001 in healthy participants who are between 50 and 69 years of age
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None